Xenon Pharmaceuticals Reports Q3 GAAP EPS of -$1.11, Exceeding Estimates
Xenon Pharmaceuticals (XENE) reported third-quarter GAAP earnings per share of -$1.11, slightly surpassing market expectations by $0.03. The company's financial results reflect a significant increase in other income, which rose to $11.5 million for the quarter ending September 30, 2026, up from $6.1 million during the same period in 2025. The improvement in non-operating income suggests a strengthening of the company's balance sheet or changes in investment/other revenue streams. While the company remains in a loss position, the earnings beat provides a marginal positive signal regarding its ability to manage costs and optimize secondary income streams.
Tickers: $XENE
Topics: earnings beat GAAP EPS other income